Author Affiliation: Cardiology Section, University of North Carolina, Chapel Hill.
In this issue of THE JOURNAL, Albert and colleagues1
present the main results of the Pravastatin Inflammation/CRP Evaluation (PRINCE)
study, a randomized clinical trial and prospective cohort study evaluating
the effects of pravastatin on levels of high sensitivity C-reactive protein
(CRP). The investigators randomly assigned men and women with elevated low-density
lipoprotein cholesterol (LDL-C) levels and no apparent coronary disease to
receive placebo or pravastatin to assess the change in CRP levels at 24 weeks
independently of the change in lipids. An additional cohort of patients with
established coronary disease received open label pravastatin to determine
the effect on CRP among these patients as well.
Simpson, Jr RJ. Placing PRINCE in Perspective. JAMA. 2001;286(1):91-93. doi:10.1001/jama.286.1.91